Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Status
- RECRUITING
- Phase
- PHASE3
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
- Status
- RECRUITING
- Phase
- PHASE2
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
- Status
- UNKNOWN
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
- Status
- COMPLETED
- Phase
- PHASE4
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Status
- COMPLETED
- Phase
- PHASE2
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
- Status
- COMPLETED
- Phase
- NA
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
- Status
- RECRUITING
- Phase
- NA
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE3